Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Journal of Clinical Oncology (heme-filtered)
Published September 30, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3.
October 1, 2026
Medspoke
Medspoke
Blood Advances
Published September 30, 2026
00:00
--:--
Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD...
October 1, 2026
Share
Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy.
https://www.medspoke.co/channel_journal?id=683&tap_id=14868
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Blood Advances
Published September 30, 2026
Resolving structural variants in hemophilia: insights from long-read sequencing and molecular and...
October 1, 2026
Why are you reporting this TALK?
